Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NQO1 | P15559 | 1/20 | 0.31 |
| ▸ | POR | P16435 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10062636 | 0.79 | NQO1 (0.31) | NQO1POR | |
| SCHEMBL1700927 | 0.77 | MAPT (0.36) | KDM4ELMNA | |
| SCHEMBL1701034 | 0.74 | ALDH1A1 (0.34) | — | |
| SCHEMBL10787662 | 0.70 | ALOX15 (0.44) | NPC1RAB9APKMTSHRSMN1; SMN2 | |
| SCHEMBL2405291 | 0.69 | — | — | |
| SCHEMBL418090 | 0.65 | — | — | |
| SCHEMBL9812791 | 0.64 | KDM4E (0.39) | NQO1PORKDM4EMAPK1LMNA | |
| SCHEMBL804843 | 0.64 | NQO1 (0.61) | NPC1RAB9APKMTSHRSMN1; SMN2 | |
| SCHEMBL10810437 | 0.64 | KDM4E (0.39) | NQO1PORKDM4EMAPK1LMNA | |
| SCHEMBL17718796 | 0.64 | ALDH1A1 (0.39) | NPC1RAB9APKMTSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10328065-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer | NOVARTIS AG (CH) | 2019-06-25 | — | — | US | disclosed |
| US-10328066-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer | NOVARTIS AG (CH) | 2019-06-25 | — | — | US | disclosed |
| US-10328066-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer | NOVARTIS AG (CH) | 2019-06-25 | — | — | US | disclosed |
| US-10328065-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer | NOVARTIS AG (CH) | 2019-06-25 | — | — | US | disclosed |
| US-20180318275-A1 | COMBINATION THERAPY USING PI3K INHIBITOR AND MDM2 INHIBITOR | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-11-08 | — | — | US | disclosed |
| EP-3380097-A2 | PHARMACEUTICAL COMBINATION COMPRISING (A) THE ALPHA-ISOFORM SPECIFIC PI3K INHIBITOR ALPELISIB (BYL719) AND (B) AN AKT INHIBITOR, PREFERABLY MK-2206, AFURESERTIB OR UPROSERTIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER | Novartis AG (CH) | 2018-10-03 | — | — | EP | disclosed |
| US-20180256557-A1 | PHARMACEUTICAL COMBINATION COMPRISING (A) THE ALPHA-ISOFORM SPECIFIC PI3K INHIBITOR ALPELISIB (BYL719) AND (B) AN AKT INHIBITOR, PREFERABLY MK-2206, AFURESERTIB OR UPROSERTIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-09-13 | — | — | US | disclosed |
| US-20180243280-A1 | A PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE CDK4/6 INHIBITOR RIBOCICLIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-08-30 | — | — | US | disclosed |
| US-20180243279-A1 | PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-08-30 | — | — | US | disclosed |
| EP-3355886-A1 | PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER | Novartis AG (CH) | 2018-08-08 | — | — | EP | disclosed |
| US-20120263712-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-8227462-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2012-07-24 | — | — | US | disclosed |
| US-8227462-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2012-07-24 | — | — | US | disclosed |
| US-8227462-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2012-07-24 | — | — | US | disclosed |
| WO-2012016970-A1 | A CRYSTALLINE FORM OF (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 2-AMIDE 1-(4 -METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYL-ETHYL)-PYRIDIN-4-YL]-THIAZOL-2-YL)-AMIDE AND ITS USE AS PI3K INHIBITOR | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012016970-A1 | A CRYSTALLINE FORM OF (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 2-AMIDE 1-(4 -METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYL-ETHYL)-PYRIDIN-4-YL]-THIAZOL-2-YL)-AMIDE AND ITS USE AS PI3K INHIBITOR | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010029082-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263712-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | PIK3C3, PRKDC, PIK3CD | NPC1 1603/4885RAB9A 516/4885PKM 1368/4885 |
| US-20180243279-A1 | PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER | BRAF, RAF1, PIK3CA | NPC1 2283/4885RAB9A 176/4885PKM 1644/4885 |
| US-20180243280-A1 | A PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE CDK4/6 INHIBITOR RIBOCICLIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER | CDK4, CDK3, CDK6 | NPC1 3022/4885RAB9A 962/4885PKM 628/4885 |
| US-10328066-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer | CDK4, CDK6, CDK9 | NPC1 3088/4885RAB9A 1073/4885PKM 1124/4885 |
| US-20100105711-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | NPC1 500/4885RAB9A 1091/4885PKM 1407/4885 |
| US-20180318275-A1 | COMBINATION THERAPY USING PI3K INHIBITOR AND MDM2 INHIBITOR | TP53, MDM2, BCL2 | NPC1 3777/4885RAB9A 2538/4885PKM 3378/4885 |
| US-20180256557-A1 | PHARMACEUTICAL COMBINATION COMPRISING (A) THE ALPHA-ISOFORM SPECIFIC PI3K INHIBITOR ALPELISIB (BYL719) AND (B) AN AKT INHIBITOR, PREFERABLY MK-2206, AFURESERTIB OR UPROSERTIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER | PIK3CA, PIK3R5, PIK3R2 | NPC1 1464/4885RAB9A 358/4885PKM 653/4885 |
| US-10328065-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer | BRAF, RAF1, PIK3CA | NPC1 2283/4885RAB9A 176/4885PKM 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.